Indegene completes acquisition of Cake Health
pharmafile | February 18, 2026 | News story | |Â Â Cake Health, IndegeneÂ
Indegene, a life sciences solutions company, has announced its acquisition of Cake Health, a healthcare agency, as well as its subsidiaries.
This acquisition marks the third from Indegene in under four years. It previously acquired Cult Health in 2022, followed by Trilogy Medical Writing and Consulting in 2025.
Cake Health is a healthcare agency based in Austria. It brings expertise across a wide variety of sectors, including healthcare brand strategy, creative excellence, omnichannel campaigning and digital marketing. Its client list also includes a number of major global pharmaceutical companies, such as Amgen, AstraZeneca, Biogen, Eli Lilly, Johnson & Johnson, Novartis and Pfizer. The company states that 18 of the top 20 global pharmaceutical companies are clients.
Cake was awarded third place in the Germany, Austria and Switzerland (DACH) creative ranking in 2023/2024, having risen up the ranks since 2021 (ninth place) and 2022 (fifth place).
Cake will continue to manage the Cake Health business following the acquisition in order to maintain continuity. This also has the advantage of expanded global presence for Indegene’s clients.
The addition of a working presence in the DACH region will enhance Indegene’s ability to support a range of European and global clients. It will allow for improved European delivery, as well as global programmes featuring European initiatives.
The combination of Cake’s expertise in healthcare communications and Indegene’s capacity for global commercialisation will distinguish Indegene from creative-only agencies. Indegene will now be able to support life sciences clients in commercialisation and execution across a number of important markets, including the US and Europe.
